RR-11a

RR-11a is a synthetic enzyme inhibitor of Legumain.

Signaling Pathways >> Others >> Others

Research Areas >> Cancer

Legumain[1]

Legumain-targeted RR-11a-coupled nanoparticles reveal high ligand-receptor affinity, enhance solid-tumor penetration and uptake by tumor cells[1].

Treatment of tumor-bearing mice with RR-11a-coupled NPs encapsulating doxorubicin results in improved tumor selectivity and drug sensitivity, leading to complete inhibition of tumor growth[1].

Mice[1] Mice bearing 4T1 orthothopic tumors of approximately 500 mm3 are injected once intravenously with RR-11a+ or RR-11a-nanoparticles labeled with rhodamine B. Alternatively, mice are injected intravenously 3 times at 48-hour intervals with RDZ-218, NP-DOX, free DOX, or saline. Twenty-four hours after the final treatment, animals are sacrificed and spleen, kidney, lungs, liver, heart and tumor are collected, frozen in OCT compound, immediately sectioned and imaged by fluorescence microscopy[1].

[1]. Liao D, et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine. 2011 Dec;7(6):665-73.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline